Document Detail

Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin.
MedLine Citation:
PMID:  19434385     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION AND HYPOTHESIS: In overactive bladder (OAB), subjects' most bothersome symptom (MBS) may influence treatment-related outcomes. We evaluated effects of solifenacin on patient-reported outcomes (PROs) in subjects stratified by their MBS at baseline.
METHODS: In a 12-week, open-label study, the effects of solifenacin on PROs were assessed using visual analog scales (VAS), the OAB questionnaire (OAB-q), and the patient perception of bladder condition (PPBC). Statistics were descriptive.
RESULTS: Subjects' baseline MBS were frequency (27%), urge urinary incontinence (UUI; 26%), urgency (23%), and nocturia (15%); VAS scores were worse for MBS. By study end, participants' MBS showed the largest solifenacin-related VAS improvements. The UUI subgroup showed the largest VAS, OAB-q, and PPBC improvements.
CONCLUSIONS: Solifenacin improved overall and symptom-specific bother, HRQL, and perception of their bladder condition in MBS subgroups, with larger improvements in subjects' MBS. Those with UUI as MBS showed greater improvement in most outcomes.
Peter K Sand; William D Steers; Roger Dmochowski; Masakazu Andoh; Sergio Forero-Schwanhaeuser
Related Documents :
8863575 - Early results with antegrade collagen injection for post-radical prostatectomy stress u...
20628335 - The evaluation of bladder symptoms in patients with lumbar compression disorders who ha...
7092485 - High correlation of norepinephrine and its major metabolite excretion rates.
22987465 - Control groups in hyperbaric trials.
25070785 - Prognostic value of one-year course of symptoms of anxiety and depression in patients w...
2654335 - Chemonucleolysis versus discectomy: a randomized multicenter trial.
Publication Detail:
Type:  Journal Article     Date:  2009-03-10
Journal Detail:
Title:  International urogynecology journal and pelvic floor dysfunction     Volume:  20     ISSN:  -     ISO Abbreviation:  Int Urogynecol J Pelvic Floor Dysfunct     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-05-12     Completed Date:  2009-08-11     Revised Date:  2011-08-18    
Medline Journal Info:
Nlm Unique ID:  9514583     Medline TA:  Int Urogynecol J Pelvic Floor Dysfunct     Country:  England    
Other Details:
Languages:  eng     Pagination:  667-75     Citation Subset:  IM    
Division of Urogynecology, Department of Obstetrics & Gynecology, Evanston Continence Center, NorthShore University HealthSystem, Northwestern University, Feinberg School of Medicine, Evanston, IL 60201, USA.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Middle Aged
Muscarinic Antagonists / adverse effects,  therapeutic use*
Patient Satisfaction
Quality of Life*
Quinuclidines / adverse effects,  therapeutic use*
Tetrahydroisoquinolines / adverse effects,  therapeutic use*
Treatment Outcome
Urinary Bladder, Overactive / drug therapy*,  psychology
Reg. No./Substance:
0/Muscarinic Antagonists; 0/Quinuclidines; 0/Tetrahydroisoquinolines; 0/quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Significant improvement in the quality of life in women treated with a novel disposable intravaginal...
Next Document:  Magnetic resonance imaging of pelvic organ prolapse: comparing pubococcygeal and midpubic lines with...